[1] Yau V, Chow E, Davis L, et al. Pain management in cancer patients with bone metastases remains a challenge[J]. J Pain Symptom Manage, 2004, 27(1):1-3.
[2] Damerla V, Packianathan S, Boerner PS, et al.Recent developments in nuclear medicine in the management of bone metastases:a review and perspective[J]. Aria J Clin Oncol, 2005, 28(5):513-520.
[3] Jemal A, Murray T, Samuels A, et al. Cancer statistics[J]. CA Cancer J Clin, 2003, 53(1):5-26.
[4] Choong PF. The molecular basis of skeletal metastases[J], Clin Orthop Relat Res, 2003, (415 Suppl):S19-S31.
[5] Pandit-Taskar N, Batraki M, Divgi CIR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases[J]. J Nucl Med, 2004, 45(8):1358-1365.
[6] Lewington VJ. Bone-seeking radionuclides for therapy[J]. J Nucl Med, 2005, 46(suppl 1):38S-47S.
[7] Liepe K, Hliscs R, Kropp J, et al. Dosimetry of 188Re-hydroxyethylidenediphosphonate in human prostate cancer skeletal metastases[J]. J Nucl Med, 2003, 44(6):953-960.
[8] Pahnedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma:randomized phase Ⅱ trial with the new, high-energy radiopharmaceutical rhenium-188h ydroxyethylidenediphosphonate[J]. J Clin Oncol, 2003, 21(15):2869-2875.
[9] Bishayee A, Rao DV, Srivastava SC, et al. Marrow-sparing effects of 117mSn (4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer[J]. J Nucl Med, 2000, 41(12):2043-2050.
[10] Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223Ra:comparison with the βemitter 89Sr in mice[J]. J Nucl Med, 2003,44(2):252-259.